A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs

计划入组 96 人 · 首次发布于 2026 年 7 月 30 日

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

计划入组 66 人 · 首次发布于 2015 年 11 月 4 日

Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

计划入组 38 人 · 首次发布于 2013 年 6 月 12 日

AM9-79

topoisomerase I inhibitor (sepsis)

topoisomerase I inhibitors (cancer)

Universitetet i Oslo

Norway

I-SHOU UNIVERSITY

Taiwan

i-SENS, Inc.

South Korea

FDA Clears IND Application for Zymeworks' Novel FRα-Targeted ADC, ZW191

FDA Clears IND for SystImmune's BL-M11D1 in Relapsed/Refractory AML

Phrontline Biopharma's TJ106 Shows Promise Against HER2-Low and ADC-Resistant Tumors in Preclinical Studies